



Advancing Novel HIV Prevention Strategies, Together: A Scientific and Community Exchange

NOTICE AND DISCLAIMER

This session has been organized and fully funded by Gilead Sciences.

It is an informational session and is not intended to be promotional.

The presenters (other than the Gilead moderators) may express their own views that are not necessarily shared or endorsed by Gilead.

Copyright in these presentations is owned by Gilead Sciences, Inc.



Housekeeping

- Q&A guidance: Please submit your questions throughout the discussion via the chat function
- A full recording of this session will be made available on the R4P website



Taking a Look Back

What's Next?

1. Reflecting on Advances to Date
 2. Identifying Unmet Needs
-
1. Finding New Prevention Strategies and Innovation in Clinical Trials for AGYW
 2. Approaching the Research in the Right Way
 3. Collaborating with Community Perspectives and Learnings
 4. Applying the Lessons of the Past to Future Endeavors



Moderators



Jared Baeten, MD, PhD

Vice President,
Virology Therapeutic Area



Moupali Das, MD, MPH

Executive Director,
Virology Therapeutic Area

Experts



Linda-Gail Bekker

MBCbB, DTMH, DCH, FCP, PhD,
Deputy Director,
Desmond Tutu HIV Centre; Past
President, International AIDS
Society



Dázon Dixon Diallo

Founder and President of
SisterLove, Co-chair for the Act
Now End AIDS National
Coalition, Convener,
WomenNOW! 2021 Continuum &
Summit



Flavia Matovu Kiweewa

MBCbB, MSc, Epidemiologist and Investigator
at the Makerere University-Johns Hopkins
University (MU-JHU) Research Collaboration,
Honorary Lecturer at Makerere University
School of Public Health



Ntando Yola

Community
Engagement Lead,
Desmond Tutu Health
Foundation



Quarraisha Abdool Karim

PhD, UNAIDS Special Ambassador
for Adolescents and HIV,
Associate Scientific Director of the
Centre for the AIDS Programme of
Research in South Africa,
Professor of Clinical
Epidemiology, Columbia University



Thesla Palanee-Phillips

MMed Sci, PhD, MSc,
Director of Clinical Trials,
Wits Reproductive Health
and HIV Institute



Yvette Raphael

Co-founder and Co-director of
Advocacy for Prevention of HIV and
AIDS (APHA) in South Africa,
Monitoring and Evaluation Program
Officer for the Johns Hopkins
University Health and Education
Programs in South Africa



RAPID FIRE:

What are you most looking forward to seeing progress in the field of HIV prevention research?




Taking a Look Back

1. Reflecting on Advances to Date
2. Identifying Unmet Needs



FAST TRACK

Ending The AIDS Epidemic By 2030: UNAIDS Goals



Fast-Track Targets

by 2020

90-90-90

Treatment

500 000

New infections among adults

ZERO

Discrimination

by 2030

95-95-95

Treatment

200 000



New infections among adults

ZERO

Discrimination

2030: The Vision





What is the single biggest barrier to ending the epidemic?



What's Next?

1. Finding New Prevention Strategies and Innovation in Clinical Trials for AGYW
2. Approaching the Research in the Right Way
3. Collaborating with Community Perspectives and Learnings
4. Applying the Lessons of the Past to Future Endeavors




Unique Considerations for PrEP Trials

Robust community and stakeholder engagement prior to study development and through dissemination

Counterfactual HIV incidence design

Intentional inclusion of pregnant and lactating women and adolescents

Participant-focused products and procedures



“There are many challenges for young people where I live, but one of the big ones is the stigma associated with HIV and taking a pill every day to prevent it.”

“I believe it’s more important for young people to have more options because what works for me might not work for the next person. Whether it’s a pill or a ring or maybe even a shot that we don’t have to worry about every day could help young people be more open to PrEP.”

“What happens if I get pregnant? How can I protect myself from HIV if my options become more limited?”

“If I could, I would tell researchers that they should look into options that won’t disturb young people’s lives, something they don’t have to take every day - you know, because then we won’t forget.”

Clinical Trials for HIV Prevention

Collaboration
Transparency



Community & stakeholder collaboration

Investigator engagement

Repeated and Committed Community Engagement



Stakeholder Consultation
Kigali, Rwanda



Stakeholder Consultation
Durban, South Africa

US MSM and Trans
Stakeholder Meeting



Ugandan Stakeholder
Meeting



South African
Stakeholder
Meeting



US Women's Study
Consultation



AGYW
Global CAG



Dec 2019

Jan 2020

May

Nov

Dec

Jan 2021


Ongoing collaboration




AVAC-sponsored meeting
New York, USA



SA & Ugandan Advocates





Globally, 390,000 adolescent girls and young women are infected with HIV every year. In sub-Saharan Africa, girls account for 75% of new annual HIV infections amongst adolescents.

Source: UNAIDS 2018 estimates.

Every three minutes a teenage girl is infected by HIV.

Source: UNAIDS 2018 estimates.

In the U.S., 57% of new HIV diagnoses among women were among Black or African American women.

Source: CDC 2018 HIV Surveillance Report.

Image courtesy of SisterLove



We want to hear from you



Thank You!